MLLT11 Activators
MLLT11 activators belong to a distinct chemical class of compounds known for their ability to modulate the activity of the MLLT11 protein, also referred to as AF1Q or MLLT11/AF1Q. MLLT11 is a multifunctional protein that plays a crucial role in various cellular processes, including gene regulation, cell proliferation, and differentiation. The activation of MLLT11 is associated with the regulation of several important cellular pathways, making it an intriguing target for research.
The chemical class of MLLT11 activators typically comprises small molecules or compounds that interact with MLLT11 to enhance its functional activity or stabilize its active conformation. These activators are designed to promote the proper functioning of MLLT11 in cellular processes, which can have a significant impact on various biological systems. The mechanisms through which MLLT11 activators operate may involve binding to specific regions of the MLLT11 protein, altering its conformation, or facilitating its interaction with other cellular components. Understanding the structural and biochemical properties of MLLT11 activators is crucial for elucidating their precise mode of action and implications in cellular regulation. Research in this field is ongoing, with scientists exploring the development of novel MLLT11 activators and their role in cellular biology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
A tyrosine kinase inhibitor that indirectly activates the activity of MLLT11-related fusion proteins by targeting specific kinases like BCR-ABL. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that indirectly activates MLLT11 by disrupting protein degradation pathways, potentially affecting the stability of MLLT11-related fusion proteins. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
Another HDAC inhibitor that indirectly increases MLLT11 by modifying the epigenetic landscape, potentially impacting the expression of genes associated with MLLT11-related fusion proteins. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A tyrosine kinase inhibitor that indirectly activates MLLT11 by targeting kinases associated with MLLT11-related fusion proteins, potentially influencing their activation. | ||||||
LGK 974 | 1243244-14-5 | sc-489380 sc-489380A | 5 mg 50 mg | $359.00 $1295.00 | 2 | |
A Wnt pathway inhibitor that indirectly activates MLLT11-related pathways by blocking Wnt signaling, which can interact with MLLT11 in certain contexts. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
A BTK inhibitor that indirectly activates MLLT11 activity by targeting signaling pathways involved in leukemia development, which can impact MLLT11-related fusion proteins. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
An EZH2 inhibitor that indirectly increases MLLT11 by altering histone methylation, potentially influencing the epigenetic regulation of genes associated with MLLT11-related fusion proteins. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
A MEK inhibitor that indirectly activates MLLT11 by targeting the Ras signaling pathway, which can interact with MLLT11-related pathways in leukemia. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
A gamma-secretase inhibitor that indirectly activates MLLT11-related pathways by blocking the Notch signaling pathway, which can interact with MLLT11 in certain cellular contexts. | ||||||